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Viruses are one of the major causes of acute and chronic infectious diseases and
thus a major contributor to the global burden of disease. Several studies have shown
how viruses have evolved to hijack basic cellular pathways and evade innate immune
response by modulating key host factors and signaling pathways. A collective view
of these multiple studies could advance our understanding of virus-host interactions
and provide new therapeutic perspectives for the treatment of viral diseases. Here,
we performed an integrative meta-analysis to elucidate the 17 different host-virus
interactomes. Network and bioinformatics analyses showed how viruses with small
genomes efficiently achieve the maximal effect by targeting multifunctional and highly
connected host proteins with a high occurrence of disordered regions. We also identified
the core cellular process subnetworks that are targeted by all the viruses. Integration with
functional RNA interference (RNAi) datasets showed that a large proportion of the targets
are required for viral replication. Furthermore, we performed an interactome-informed
drug re-purposing screen and identified novel activities for broad-spectrum antiviral
agents against hepatitis C virus and human metapneumovirus. Altogether, these
orthogonal datasets could serve as a platform for hypothesis generation and follow-up
studies to broaden our understanding of the viral evasion landscape.
Keywords: virus–host interaction, protein–protein interaction, gene–drug interaction, innate immunity, viral
evasion, network analysis, molecular innate immunity
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1. INTRODUCTION
Viruses continue to be a major contributor to the global burden
of disease through acute and chronic infections that cause
substantial economic impact in addition to increased mortality
and morbidity (1). Despite the tremendous improvement
in the understanding of the antiviral immune response
and the availability of therapeutics, existing and emerging
viral diseases are an ever-growing problem, particularly in
developing countries. Development of antiviral resistance of
hepatitis C virus (HCV), influenza A virus (IAV), herpes
simplex virus (HSV), human cytomegalovirus (HCMV), human
immunodeficiency virus (HIV), and other viruses is a major
concern (2–4). One of the main reasons for increasing
resistances is the accumulation of mutations in the viral genome
caused by multiple factors including the polymerase infidelity
(5, 6). Therefore, the World Health Organization (WHO)
and the United Nations have urged for better control of
viral diseases.
This has led to turning the focus on the host for
therapeutic intervention. Targeting the host factors has been
proven to be useful for restricting viral infections (7, 8). The
small molecule CCR5 inhibitor Maraviroc and the anti-CD4
monoclonal antibody Ibalizumab are examples of successful
use of host-directed therapies for combating HIV in clinic
(9–11).
Viruses have evolved to evade the host antiviral response
at various stages starting from viral sensing to antiviral pro-
inflammatory responses (12–14). Multiple studies attempted to
understand global principles of the viral evasion employed by
various viruses, including dengue virus (DENV), Ebola virus
(EBOV), IAV, and HIV (15–20). Global systems-level approaches
including functional RNAi screens, interactome mapping
technologies such as affinity-purification mass spectrometry
(AP-MS), quantitative proteomics, and CRISPR/Cas9-based
screens have provided unparalleled details and insights
into the dynamics of host proteome in immune cells
(21–24), host-virus interactome (15–17, 25, 26), and also
identified important host dependency factors of various
viruses (25, 27, 28). Meta-analyses of such high-dimensional
datasets have been crucial for identifying novel host factors as
drug targets such as UBR4 in IAV infection (29). Moreover,
some of these factors represent drug targets for multiple
viruses (30).
We hypothesized that combining ameta-analysis of host-virus
protein-protein interactions of multiple viruses and functional
RNAi screens would provide novel insights for developing broad-
spectrum antiviral strategies. For this, we assembled a host-virus
protein-protein interactome of 5,781 host-virus interactions
(hereafter referred to as “hvPPI”) covering 183 viral proteins
from 17 different viruses and 2,381 host proteins. We performed
extensive bioinformatics and network analysis and integrated this
dataset with genome–wide or druggable–genome RNAi screen
data from published studies. This resulted in the assembly of
critical nodes of viral evasion and identification of core cellular
processes and druggable nodes that were verified by a drug
re-purposing screen using broad-spectrum antivirals.
2. MATERIALS AND METHODS
2.1. Construction of hvPPI Data, Network
Analysis, and Data Visualization
Host-virus protein–protein interactions were downloaded from
published studies (15–17, 25, 31–34) which included a total
of 183 viral proteins, 2,381 host proteins, and 5,781 host-
virus interactions. Protein identifiers were mapped to UniProt
IDs. Human protein-protein interaction data was imported
from BioGRID database [version 3.4.139, (35)] covering 215244
interactions. The network analysis was performed using in-
house programs developed in R statistical environment (version
3.4.3, www.r-project.org) with the use of the packages SparseM
(version 1.77), RBGL (version 1.52.0), and graph (version 1.54.0).
Network visualization was performed in Cytoscape [version
3.6.1, (36)]. Network clusters/sub-networks were extracted
using the Cytoscape plugin MCODE [version 1.5.1, (37)].
Data visualization was performed in R statistical environment
and Cytoscape.
2.2. Gene-Set Enrichment, Protein
Disorder, and Sub-cellular Localization
Analysis
We performed gene-set enrichment analysis using DAVID
Bioinformatics Resources [version 6.8, (38)]. For all enrichment
analysis, a p-value cutoff of≤0.01 was used as significant. Protein
disorder analysis was performed using IUPred2A software. We
used the oﬄine version with protein sequences downloaded from
UniProt. Statistical analysis of disordered region distribution
was performed by Kolmogorov-Smirnov test in R statistical
environment. Annotation of human proteins was mapped from
UniProt ID to ENSEMBL using EnsDb.Hsapiens.v86. The index
of subcellular localization of interaction partners of single
viral proteins was calculated for all viral proteins with ≥ five
host targets. Localization of host targets was mapped using
COMPARTMENTS (39), filtered for a minimum evidence score
of 3 in the knowledge channel, excluding non-experimental
based localization predictions. Evidence for all protein was
subsequently divided by the absolute number of host-targets per
viral protein. Multiple sequence alignment was performed using
Clustal X [version 2.0, (40)].
2.3. Integration of RNAi Screens and
Drug-Gene Interaction Data
Genome-wide RNAi screen data for HCV (41) and HPV18 (42),
through GenomeRNAi database [(43)– GR00197], as well as
druggable RNAi screen data for HPV16 (44), VACV (45), and
SV40 (46) were integrated in the existing network as Z-Scores.
Drug-gene interaction data was downloaded from DGIdb and
drugbank. The identifiers were mapped to UniProt IDs and then
compared with hvPPI.
2.4. Drug Re-purposing Screen
For the HMPV NL/1/00-GFP screen, approximately 4×104
human retinal pigment epithelial (RPE) cells were seeded per
well in 96-well plates. Human non-malignant RPE cell line
represents excellent model system for studying replication of
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many viruses including respiratory (30, 47, 48). The cells were
grown for 24 h in DMEM-F12 medium supplemented with 10%
FBS, 0.35% NaHCO3, and 100 µg/ml streptomicine and 100
IU/ml penicillin. The medium was replaced with virus growth
medium (VGM) containing 0.2% bovine serum albumin (BSA), 2
mM L-glutamine, 0.35% NaHCO3, and 1 µg/ml L-1-tosylamido-
2-phenylethyl chloromethyl ketone-trypsin in DMEM-F12. HCV
screen-associated cell culture conditions are described in Kim
et al. (49). The compounds were added to the cells in 3-
fold dilutions at seven different concentrations starting from
50 µM. No compounds were added to the control wells.
The cells were mock- or virus-infected at a multiplicity of
infection (MOI) of one. After 48 h of infection, the medium
was removed from the cells. To monitor cell viability, CellTiter-
Glo reagent was added (30 µl per well). This assay quantifies
ATP, an indicator of metabolically active living cells. The
luminescence was measured with a plate reader. To determine
compound efficacy, HMPV NL/1/00-mediated GFP expression
was measured. The half-maximal cytotoxic concentration (CC50)
and the half-maximal effective concentration (EC50) for each
compound were calculated after non-linear regression analysis
with a variable slope using GraphPad Prism software version
7.0a. The relative effectiveness of the drug was quantified as the
selectivity index (SI = CC50EC50 ).
Cytotoxicity and antiviral activity of the compounds against
GFP-expressing HCV in Huh-7.5 cells was determined as
previously described (49).
3. RESULTS
3.1. Assembly of Host-Virus
Protein-Protein Interactions
To provide new and critical insights into viral evasion
mechanisms we performed a comprehensive meta-analysis of
the host-virus interaction landscape. We assembled the host-
virus protein-protein interaction data (“hvPPI”) from published
studies (Figure 1A) (15–17, 25, 31–34). This dataset covered
17 different viruses including adeno-associated virus 5 (AAV5),
dengue virus (DENV), Epstein-Barr virus (EBV), influenza
A virus PR8 (IAV-PR8), influenza virus Udorn (IAV-Udorn),
hepatitis C virus (HCV), human immunodeficiency virus 1 (HIV-
1), human papilloma virus 5 (HPV5), human papilloma virus 6B
(HPV6B), human papilloma virus 8 (HPV8), human papilloma
virus 11 (HPV11), human papilloma virus 16 (HPV16), human
papilloma virus 18 (HPV18), human papilloma virus 33
(HPV33), Merkel cell polyomavirus (MCPyV), Simian virus 40
(SV40), and Vaccinia virus (VACV). This dataset comprised
of protein-protein interactions from two different types of
experimental methods—affinity purification mass spectrometry
(AP-MS) and yeast two-hybrid screens (Y2H). Altogether,
this combined dataset includes 183 viral proteins, 2,381 host
proteins, and 5,781 protein-protein interactions (Figure 1B and
Figure S1). Many interactome networks including yeast and
human are scale-free networks, where a large portion of the nodes
(e.g., a protein in the network) have few interactions and only a
few nodes have large number of interactions. The latter are often
referred to as “hubs” which are crucial in keeping the network
intact (34). We performed network topology analysis to infer the
properties of the host proteins targeted by the viral proteins in the
context of the human protein interactome. We considered two
important parameters—relative betweenness centrality (which
reflects the amount of information that passes through this
protein in the human interactome) and degree (number of
binding partners in the human interactome) of the host proteins
targeted by each virus. The targets of all the viruses showed higher
betweenness centrality and degree as compared to an average
protein in the human interactome (Figures 1C,D). This shows
that viruses, by targeting “hubs” and proteins that serves as key
communication nodes, have evolved the best way to disrupt
the scale-free human interactome. This topological property
thereby shows how viruses having small genomes achieve the
maximal effect in rewiring the human interactome to benefit
viral survival and replication. Our analysis is in agreement with
several previous studies, which have highlighted this property
(15, 16, 31, 50, 51). We propose that this could be a general
principle for all viruses.
3.2. Host Factors With Higher Disordered
Regions Are Enriched in hvPPI Networks
Proteins typically fold into stable three-dimensional structures
that mediate specific functions. In addition, there are sub-
structures in proteins termed “intrinsically disordered regions
(IDRs)” which lack stable structures under normal physiological
conditions. IDRs are required for multiple cellular functions
even though they lack these defined structures (52). Many
studies have highlighted the presence of such IDRs in viral
proteins (53–55), such as E6 from human papilloma virus,
that are crucial for hijacking the cellular machinery. We
analyzed the host proteins from the hvPPI for presence of
IDRs using the prediction software IUPred (56). It is estimated
that the human proteome more than 100,000 short linear
binding motifs in IDRs (57, 58). Proteins with IDRs are
often signaling hubs and might form dynamic complexes
with other proteins through specific motif based interactions
(58). We found a statistically significant enrichment (p-value
< 6.246 × 10−06) of IDRs in the host proteins targeted
by viruses (Figure 2A and Figure S2). We then identified the
subnetwork in the hvPPI which contained the top host targets
with high disorderness score (Figure 2B). The top five proteins
with large IDRs include CD44 antigen (CD44), Serine/arginine
repetitive matrix protein 2 (SRRM2), Myristoylated alanine-
rich C-kinase substrate (MARCKS), BAG family molecular
chaperone regulator 3 (BAG3), and Mitochondrial antiviral-
signaling protein (MAVS; Figure 2C). CD44 is a marker of
exhausted CD8+ T cells (59) and replication of HCV in T cells
was shown to decrease cell proliferation by inhibiting CD44
expression and signaling (60). SRRM2 is a serine/arginine-rich
protein involved in RNA splicing (61). SRRM2 is differentially
phosphorylated in HIV–1 infected cells and absence of SRRM2
lead to increased HIV–1 gene expression, since it regulates the
splicing of HIV–1 (62). In the hvPPI, SRRM2 is targeted by
multiple viral proteins including the Tat protein from HIV-1.
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FIGURE 1 | Meta-analysis of host-virus interactions involving 17 different viruses. (A) Schematic view of the analysis workflow. (B) Network view of the “hvPPI”
containing host-virus interactions from 17 different viruses. The edges are colored in orange. Node shapes are in circles and triangles for host and viral protein,
respectively. A zoomed-in snippet shows the names of selected host and viral proteins. (C,D) Barplot showing the median degree and betweenness centrality of
targets of each virus as compared to the human proteome.
Tat protein has an important role in the stimulation of the
transcription of the long terminal repeat (LTR) (63). In addition,
NS1 protein from influenza B virus has also been reported to
interact with SRRM2 (64). Proteins of the MARCKS family
are involved in a range of cellular processes including cell
adhesion and migration (65). MARCKS is a negative regulator
of lipopolysaccharide (LPS)-induced Toll-like receptor 4 (TLR4)
signaling in mouse macrophages (66). MAVS is an adaptor
protein in the RIG-I signaling pathway involved in the sensing
of RNA. Ablasser et al. (67) reported that double- stranded DNA
serves as a template for RNA polymerase II and is transcribed
into a 5′ triphosphate containing double-stranded RNA, which
activates the RIG-I signaling pathway. In the hvPPI, MAVS is
targeted by several proteins from dsDNA viruses such as EBV and
HPV. Altogether, our analysis shows that the IDR-high part of the
human proteome is an essential part of the viral evasion strategy
and some of the selected targets highlighted here could show
novel insights into the viral evasion mechanisms. However, the
very flexible protein structure of disordered proteins also makes
them also difficult to target with drugs.
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FIGURE 2 | Protein disorder analysis. (A) Density plot of the distribution of host proteins for each virus with percent of residues with disorder tendency greater than
0.5 as predicted by the IUPred software as compared to the human proteome. (B) Sub-network of hvPPI with the highly targeted and highly-disordered proteins.
(C) Line plots showing the IUPred Score (a measure of the disordered region) for the five selected host proteins from the sub-network. A IUPred score of >0.5 is
considered disordered.
3.3. Viral Proteins Target Core Signaling
Pathways and Process Networks
To assess the signaling pathways and cellular processes within the
hvPPI, we identified highly connected subnetworks within hvPPI
network. We constructed a host–host interaction network based
on the host targets in the hvPPI and identified a number of highly
connected subnetworks/clusters (Figure 3). We then performed
a gene-set enrichment analysis of significantly enriched biological
processes. We found one or more enriched processes for
each of this subnetwork including core cellular processes such
as proteasome, spliceosome, protein translation, protein/RNA
transport, and cell cycle. Next we listed the viruses that target
one or more of these processes, and found that almost all the
core pathways and processes are targeted by all the 17 viruses
that are part of the hvPPI (Figure S3). This analysis highlights
the core components of the cellular process subnetworks which
are targeted as part of the viral evasion strategies and thus could
be broad-spectrum antiviral hot-spots from a therapeutic point
of view.
3.4. Enrichment Analysis Reveals
Commonality and Specificity in
Sub-cellular Localization of the Host
Factors
Given that the viral proteins were interacting with a large
number of host proteins, we analyzed the sub-cellular location
of the host proteins. We performed gene-set enrichment analysis
of sub-cellular localization information provided by UniProt
database. We binned the localization into 11 compartments and
estimated the percent of host proteins in a given compartment as
compared to the total number of host proteins targeted by a given
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FIGURE 3 | Clusters of hvPPI involved in core cellular processes. Network view of the “clusters” or highly-connected sub-networks and their associated cellular
processes. Each cluster is marked in a unique color.
virus. We found that the viral targets were distributed across
multiple subcellular compartments with cytoplasm being the
most common (Figure S4A). The hvPPI includes two different
strains of IAV– PR8 (H1N1) and Udorn (H3N2). The subcellular
localization analysis showed that both strains were enriched for
nuclear proteins. Non-structural protein 1 (NS1) from both the
strains had the highest number of nuclear targets but their targets
were very different (Figure 4A). NS1 of Udorn was enriched for
a large number of histones as compared to NS1 of PR8 that
had large number of heterogeneous nuclear ribonucleoproteins
(hnRNPs), such as HNRNPU−a known restriction factor for
many viruses. This corroborates with the observation that NS1
protein has short linear histone mimicry motifs that can suppress
the host antiviral response (68). In our analysis, we found
that it is NS1 of Udorn that has a histone mimicry motif
“ARSK” (Figure S4B). Similarly, HPV11 and HPV18 E5 proteins
interact more often with host proteins located in the endoplasmic
reticulum (ER). We found both common and specific subsets of
ER proteins targeted by the E5 protein (Figure 4B). HPV18 E5
protein ER targets were enriched for phospholipid biosynthesis as
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well as GPI anchor related proteins, such as phosphatidylinositol
glycan anchor biosynthesis class S/T/U (PIGS, PIGT, and PIGU),
glycosylphosphatidylinositol anchor attachment 1 (GPAA1)
and phosphatidylserine synthase 2 (PTDSS2). HPV11 E5
protein ER targets were enriched for ER-associated ubiquitin-
dependent protein catabolism involving host proteins such as
ER degradation enhancing alpha-mannosidase-like protein 3
(EDEM3) and ER lipid raft associated 1 (ERLIN1). ER targets
common to HPV18 and HPV11 E5 protein were enriched
for unfolded protein response, N-linked glycosylation and
protein folding involving host proteins such as SRP receptor
alpha/beta subunit (SRPRA/SRPRB) and catalytic subunits of
the oligosaccharyltransferase complex (STT3A and STT3B). Two
independent CRISPR/Cas9 screening studies identified multiple
ER associated components including STT3A and STT3B as host
factors for DENV, Zika virus (ZIKV) and Japanese encephalitis
virus (JEV) (27, 28). The non-canonical function of STT3A and
STT3B is required for DENV replication and that NS1 protein
of DENV interacts with these proteins (28). Our orthogonal
approach can lead to the identification of critical host factors, and
similar functions of ER components, such as STT3A and STT3B,
are used by HPV11 and HPV18 as well. Thus, targeting the
non-canonical function of STT3A and STT3B could be a broad
antiviral strategy. Overall, the enrichment analysis clearly shows
that there is commonality and specificity in the subcellular targets
of the viral proteins and that detailed interrogation of these
targets can give vital clues into the viral evasion mechanisms.
3.5. Integrative Analysis of Host-Virus
Interactome and RNAi Data Reveals COPI
System As Commonly Targeted Proviral
Process
RNAi screens have been a powerful high-throughput method to
identify various cellular functions, including for identification
of host restriction factors of viruses (69). In order to explore
the functional relevance of the host targets in the hvPPI, we
integrated it with five published RNAi screens that performed
genome–wide or druggable-genome–wide RNAi screens for
identifying host factors of HCV (41), HPV18 (43), HPV16
(44), SV40 (46), and VACV (45). We found that host targets
from the hvPPI were spread across the spectrum of genes
with proviral as well as antiviral phenotype (Figure S5), thus
showing that targeting of the host protein by the virus could lead
into any direction that favors the virus. We then investigated
the top 50 proviral genes that are also targeted by the viral
proteins as seen in the hvPPI. We identified 42 host proteins
(Figure 5A) that were significantly enriched for coatomer protein
complex 1 (COPI), protein translation/transport and proteasome
(Figure 5B). This further substantiates the findings from the
earlier section on the core cellular processes targeted by the
viruses. Network analysis of these top hits showed high level on
connectivity and crosstalk—for example between the translation
and proteasome machinery (Figure 5C). Vesicle carriers are
involved in the transport of membranes and proteins. COPI
system is one of the three vesicular carrier systems that is
involved in the early secretory pathway (70–72). Moreover, it
has been pointed out that there is a strong similarity between
vesicular transport and viral transport [viral entry to budding
process, (73)]; thus making COPI system important for the
viral life cycle. In addition to the findings of the present study,
siRNA-based silencing of COPI lead to a decrease in entry and
subsequent gene expression of IAV, VSV, LCMV, and HPIV3
and disruption of the COPI complex inhibited the production
of infectious progeny virus (74, 75). COPI coatomer inactivation
results in a direct decrease of VSV attachment and uptake, but
not for membrane fusion or RNP release; however the direct
mechanism remains unclear (76). Altogether, these top hits
including the COPI system could serve as targets for developing
therapeutic antiviral intervention strategies for a broad group
of viruses.
3.6. Combining Host-Virus and Drug-Gene
Interactions Reveals Novel Activities of
Broad-Spectrum Antiviral Agents Against
Hepatitis C Virus and Human
Metapneumovirus
Our analyses pointed out that viral evasion mechanism observed
in one virus could also be relevant for other viruses. To test this,
we obtained known drug-gene interactions from DGIdb (77).
We selected 28 investigational/experimental/approved
antivirals compounds (30) which had DGIdb annotated targets
that are part of the hvPPI. We added 12 agents as controls
(Table S1 and Figure S6). We tested 40 broad-spectrum-
antivirals against GFP-expressing human metapneumovirus
(HMPV) NL/1/00 strain (78). Seven different concentrations of
the compounds were added to HMPV or mock-infected cells.
HMPV-induced GFP expression and cell viability was measured
and after 48 h to determine compound efficiency and toxicity.
After the initial screening, we identified five compounds, which
lowered GFP-expression without detectable cytotoxicity (with
SI > 3). We repeated the experiment with these compounds.
The experiments revealed novel activity of azacytidine, lopinavir,
nitazoxanide, itraconazole, and oritavancin against HMPV
(Figure S7A and Table 1, Table S2). Similarly, we examined
toxicity and antiviral activity of broad-spectrum-antivirals
against GFP-expressing HCV in Huh-7.5 cells using previously
described procedures (49). Our test identified azithromycin,
cidofovir, oritavancin, dibucaine, gefitinib, minocycline, and
pirlindole mesylate as novel anti-HCV agents with SI > 3
(Figure S7B and Table 1, Table S2). In summary, our meta-
analysis approach of the hvPPI could provide novel and
faster approaches for the re-purposing of existing drugs as
antiviral agents.
4. DISCUSSION
Using integrative analysis of orthogonal datasets our study
provides a comprehensive view of viral evasion mechanisms.
In particular, our analysis of the hvPPI network revealed that
all the viruses have evolved to target proteins that are central and
have strong control over the human interactome. Host proteins
targeted by viruses contain a high proportion of intrinsically
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FIGURE 4 | Sub-cellular localization of the host proteins. (A) Network view of nuclear interactome of NS1 protein from IAV strains PR8 and Udorn. (B) Network view
of ER interactome of E5 protein from HPV18 and HPV11.
disordered regions. We identified the core cellular processes
and associated proteins that are targeted by all viruses. Detailed
comparative analysis of the subcellular localization of the host
proteins showed commonality and specificity both between viral
proteins from different strains of the same virus; and between
viruses. Integrating hvPPI with functional RNAi screens showed
that 28% of the hvPPI are host factors of one or more virus.
hvPPI data-based drug re-purposing screen identified novel
activities for various broad-spectrum antivirals against HMPV
and HCV.
This unique dataset can be used for further detailed
interrogation of the mechanisms behind viral evasion. This
could serve as a starting point for identifying novel host targets
and generating hypothesis in the context of viral evasion and
development of pan-viral therapeutic intervention strategies. The
methods described here also provide unique ways of dissecting
the orthogonal datasets. Various analyses from this study have
highlighted the existence on pan-viral evasion points that
could be utilized for the development of host-directed antiviral
therapies. It is also intriguing to see that there is commonality
and specificity at the level of sub cellular localization of the viral
targets. Our analyses have underlined some salient features in
the context of IAV, HPV, DENV, and HCV. Further detailed
analysis in this context along with protein sequence features,
such as Short Linear Motifs [SLiMs; (79)] would provide novel
insights as well as deeper understanding of how small sequence
features are involved in the hijacking of the host machinery.
Integration of such data with known drug-gene interactions
provides a clear estimate of the druggable proportion in the
hvPPI. Our meta-analysis approach of the hvPPI could provide
novel avenues of re-purposing existing drugs for antiviral
targeting strategies.
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FIGURE 5 | Integration of hvPPI with RNAi screen. (A) Top proviral genes from RNAi screens that are also targeted by multiple viral proteins. (B) Barplot showing the
significantly enriched cellular processes involving the top targeted and proviral host genes. (C) Network view of top targets and their functional relevance.
Our meta-analysis approach of the hvPPI could provide
novel avenues of re-purposing existing drugs for antiviral
targeting strategies. To prove the concept, we tested 40 BSAs
against HMPV, HCV, Sindbis virus (SINV), cytomegalovirus
(CMV), and hepatitis B virus (HBV). Importantly, 28
BSAs have DGIdb annotated targets that are part of the
hvPPI, whereas 12 were used as controls. These safe-
in-man drugs have already been used as investigational
agents or experimental drugs in different virus infections
(Table S2). We demonstrated novel antiviral effects of
azacytidine, itraconazole, lopinavir, nitazoxanide, and
oritavancin against HMPV, as well as cidofovir, dibucaine,
azithromycin, gefitinib, minocycline, oritavancin, and pirlindole
against HCV.
Azithromycin, is an FDA-approved antibiotic of themacrolide
family. It is also an investigational agent against RSV and
experimental agent against EBOV, HRV-A, ZIKV, and RSV.
Cidofovir is an FDA-approved anti-CMV drug. It is also
investigational agent against AdV, BKV, HPV, HSV-1, HSV-2,
and experimental drug against B19V. Dibucaine is an FDA-
approved amide local anesthetic. In addition, it is experimental
anti-HEV-A, HEV-B, HEV-D, and EBOV agent. Gefitinib is an
FDA approved anticancer drug. It has also antiviral activity
against BKV, CMV, and VACV. Minocycline is a broad-spectrum
antibiotic and experimental anti-DENV, HIV-1, andWNV agent.
Oritavancin is a semisynthetic glycopeptide antibiotic used
for the treatment of Gram-positive bacterial skin infections.
It also inhibits EBOV, MERS-CoV, and SARS-CoV infections.
Pirlindole is an antidepressant, which is also experimental
anti-HEV-A, HEV-B, and HEV-D agent. Azacitidine is a
chemical analog of cytidine, which is used in the treatment of
myelodysplastic syndrome. It is also an experimental anti-AdV,
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TABLE 1 | Characteristics, half-maximal cytotoxic concentration (CC50), the half-maximal effective concentration (EC50), and minimal selectivity indexes (SI =
CC50
EC50
) for
selected broad-spectrum antivirals.
Compound ChEMBL ID Approved use Virus Cell line CC50 [µ M] EC50 [µ M] SI
Azithromycin 529 Antibiotic HCV Huh-7.5 <30 >10 >3
Cidofovir 152 Anti-CMV HCV Huh-7.5 >30 <1 >30
Dibucaine 1086 Local anesthetic HCV Huh-7.5 11.6 1.4 8.4
Gefitinib 939 Anticancer HCV Huh-7.5 11.6 1.1 10.8
Minocycline 1434 Antibiotic HCV Huh-7.5 11.6 5.2 >5.7
Oritavancin 1688530 Antibiotic HCV Huh-7.5 >30 <3 >10
Pirlindole mesylate 32350 Antidepressant HCV Huh-7.5 >30 <10 >3
Azacitidine 1489 Anticancer HPMV RPE >50 1.2 41.7
Itraconazole 22587 Antifungal HPMV RPE 28.2 5 5.6
Lopinavir 729 Antiretroviral HPMV RPE 29.7 3.6 8.3
Nitazoxanide 1401 Antiparasitic HPMV RPE >50 2.6 >11.5
Oritavancin 1688530 Antibiotic HMPV RPE >50 2.6 >11.5
The measurements were repeated three times (p < 0.05).
FLUAV, RVFV, HIV-1, and HIV-2 agent. Itraconazole is an
antifungal medication. It is also used as experimental anti-HEV-
B, HRV-B, HRV-A, Par-A3, and SAFV agent. Nitazoxanide is a
broad-spectrum antiparasitic drug, which is also investigational
agent against FLUAV and HCV and experimental anti-CHIKV,
RSV, HBV, HIV-1, VACV, RV, JEV, MERS-CoV, NoV, RuV,
and ZIKV agent. Lopinavir is an FDA-approved antiretroviral
of the protease inhibitor class. It is also investigational anti-
MERS-CoV and experimental anti-ZIKV agent (Table S2). In
addition to inhibition of viral proteases (Table S2), Lopinavir
was reported to induce host RNaseL production in infected
and non-infected cells (80). RNaseL is endoribonuclease that
is a part of interferon (IFN) antiviral response, which is
the most critical node of virus-host interactions. Although,
the antiviral mechanisms of action of other compounds
are still unknown, these agents could inhibit steps of viral
infections, which precede reporter protein expression from
viral RNA.
In summary, our results indicate that existing BSAs could
be re-purposed to other viral infections. To further expand
a spectrum of their activities, these BSAs could be tested
against other viruses. Re-purposing these and other safe-in-
man antiviral therapeutics could save resources and time needed
for development of novel drugs to quickly address unmet
medical needs, because safety profiles of these agents in humans
are available. Effective treatment with broad-spectrum-antivirals
may shortly become available, pending the results of further
pre-clinical studies and clinical trials. This, in turn, means
that some broad-spectrum-antivirals could be used for rapid
management of new or emerging drug-resistant strains, as well
as for first-line treatment or for prophylaxis of acute virus
infections or for viral co-infections. The most effective and
tolerable compounds could expand the available therapeutics
for the treatment of viral diseases, improving preparedness and
the protection of the general population from viral epidemics
and pandemics.
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